Osteoarthritis - Pipeline Review, H2 2016

Date: August 24, 2016
Pages: 281
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O6DE0DB7DF6EN
Leaflet:

Download PDF Leaflet

Osteoarthritis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Osteoarthritis - Pipeline Review, H2 2016’, provides an overview of the Osteoarthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
  • The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
  • The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Osteoarthritis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Osteoarthritis Overview
Therapeutics Development
Osteoarthritis - Therapeutics under Development by Companies
Osteoarthritis - Therapeutics under Investigation by Universities/Institutes
Osteoarthritis - Pipeline Products Glance
Osteoarthritis - Products under Development by Companies
Osteoarthritis - Products under Investigation by Universities/Institutes
Osteoarthritis - Companies Involved in Therapeutics Development
Osteoarthritis - Therapeutics Assessment
Drug Profiles
Osteoarthritis - Dormant Projects
Osteoarthritis - Discontinued Products
Osteoarthritis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Osteoarthritis, H2 2016
Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016
Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016
Osteoarthritis - Pipeline by AbbVie Inc, H2 2016
Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H2 2016
Osteoarthritis - Pipeline by Ablynx NV, H2 2016
Osteoarthritis - Pipeline by Achelios Therapeutics, Inc., H2 2016
Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H2 2016
Osteoarthritis - Pipeline by Amgen Inc., H2 2016
Osteoarthritis - Pipeline by Amura Holdings Limited, H2 2016
Osteoarthritis - Pipeline by Arcarios BV, H2 2016
Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
Osteoarthritis - Pipeline by Astellas Pharma Inc., H2 2016
Osteoarthritis - Pipeline by Asterias Biotherapeutics, Inc., H2 2016
Osteoarthritis - Pipeline by Biopharm GmbH, H2 2016
Osteoarthritis - Pipeline by Bone Therapeutics SA, H2 2016
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2016
Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016
Osteoarthritis - Pipeline by Cellceutix Corporation, H2 2016
Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Osteoarthritis - Pipeline by Evgen Pharma Plc, H2 2016
Osteoarthritis - Pipeline by Galapagos NV, H2 2016
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H2 2016
Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H2 2016
Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H2 2016
Osteoarthritis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
Osteoarthritis - Pipeline by Jenrin Discovery, Inc., H2 2016
Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H2 2016
Osteoarthritis - Pipeline by Levolta Pharmaceuticals, Inc., H2 2016
Osteoarthritis - Pipeline by Medivir AB, H2 2016
Osteoarthritis - Pipeline by Merck KGaA, H2 2016
Osteoarthritis - Pipeline by Mesoblast Limited, H2 2016
Osteoarthritis - Pipeline by Mor Research Application Ltd, H2 2016
Osteoarthritis - Pipeline by NicOx S.A., H2 2016
Osteoarthritis - Pipeline by Nordic Bioscience A/S, H2 2016
Osteoarthritis - Pipeline by Novartis AG, H2 2016
Osteoarthritis - Pipeline by Omeros Corporation, H2 2016
Osteoarthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Osteoarthritis - Pipeline by OrthoCyte Corporation, H2 2016
Osteoarthritis - Pipeline by Osteologix Holdings Plc., H2 2016
Osteoarthritis - Pipeline by Pfizer Inc., H2 2016
Osteoarthritis - Pipeline by Pharmalink AB, H2 2016
Osteoarthritis - Pipeline by Philogen S.p.A., H2 2016
Osteoarthritis - Pipeline by PLx Pharma Inc., H2 2016
Osteoarthritis - Pipeline by ProteoThera, Inc., H2 2016
Osteoarthritis - Pipeline by Regeneus Ltd, H2 2016
Osteoarthritis - Pipeline by Seikagaku Corporation, H2 2016
Osteoarthritis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016
Osteoarthritis - Pipeline by Symic Biomedical, Inc., H2 2016
Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Osteoarthritis - Pipeline by TissueGene, Inc., H2 2016
Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
Osteoarthritis - Pipeline by Yuhan Corporation, H2 2016
Osteoarthritis - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
Osteoarthritis - Pipeline by Zimmer Biomet Holdings, Inc., H2 2016
Osteoarthritis - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Osteoarthritis - Dormant Projects, H2 2016
Osteoarthritis - Dormant Projects (Contd..1), H2 2016
Osteoarthritis - Dormant Projects (Contd..2), H2 2016
Osteoarthritis - Dormant Projects (Contd..3), H2 2016
Osteoarthritis - Dormant Projects (Contd..4), H2 2016
Osteoarthritis - Dormant Projects (Contd..5), H2 2016
Osteoarthritis - Dormant Projects (Contd..6), H2 2016
Osteoarthritis - Dormant Projects (Contd..7), H2 2016
Osteoarthritis - Dormant Projects (Contd..8), H2 2016
Osteoarthritis - Dormant Projects (Contd..9), H2 2016
Osteoarthritis - Discontinued Products, H2 2016
Osteoarthritis - Discontinued Products (Contd..1), H2 2016

LIST OF FIGURES

Number of Products under Development for Osteoarthritis, H2 2016
Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Bone Medical Limited - Product Pipeline Review - 2015 US$ 1,200.00 Oct, 2015 · 28 pages

Ask Your Question

Osteoarthritis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: